BioPharma Resources

Drug Trial Radar · NCT05985707

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

The Efficacy and Safety of KN026 Combination Chemotherapy ± KN046 in HER2-Positive Advanced Colorectal Cancer and Biliary Tract Cancer as First-Line Treatment: a Phase Ⅱ Study

Last checked: Nov 19, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 15, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 (a PD-L1/CTLA-4 targeted bispecific antibody).

Conditions

  • HER2-positive Colorectal Cancer
  • HER2-positive Biliary Tract Cancer

Interventions

  • KN026Drug

    KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.

  • KN046Drug

    KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

  • XELOXDrug

    XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University cancer hospital & institution

    Beijing, State*, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.